OS

Oscar Health, Inc.

OSCRHealthcareNASDAQ

Healthcare Plans · Last scanned Sep 9, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$11.70B
+27.5% YoY
Net Income
-$443.2M
-1842.5% YoY
Free Cash Flow
$692.5M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 1 MACD Negative CrossoverHistogram -0.1583, negative momentum
Aug 31 MACD Negative CrossoverHistogram -0.0970, negative momentum
About Oscar Health, Inc.

Oscar Health, Inc. operates as a healthcare technology company in the United States. The $10.19B market capitalization puts OSCR squarely in large-cap range for its industry. The company offers health plans to individuals, families, employees, and small group markets.

Where OSCR stands vs its 150-day and 200-day moving averages

As of the September 1, 2026 close, OSCR finished 38.77% above its 150-day moving average ($21.59) and 48.68% above its 200-day moving average ($20.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is OSCR overbought or oversold?

At the September 1, 2026 close, OSCR's RSI(14) was 58.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$10.19B
P/E (TTM)25.39
Fwd P/E17.54
EPS$1.30
Beta2.37
52W Change+65.5%
ROE34.3%
Analysis

The balance sheet looks solid with $8.56B in cash comfortably exceeding the $482.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $692.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 34.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $4.13B (2022) to $11.70B (2025), reflecting a 184% increase over the period.

A beta of 2.37 means OSCR is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, OSCR has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing OSCR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms